Secondary neoplasm

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receiv…

This study tests a radioactive drug called Rhenium-186 NanoLiposome (REYOBIQ) given directly into the brain's fluid space, combined with whole brain or proton radiation. It is for people with leptomeningeal metastases, where cancer has spread to the lining of the brain and spinal…

This study tests a single, high-dose radiation treatment guided by MRI for solid tumors that have spread. It aims to see if the treatment is safe and can control tumors outside the brain and spine. The trial will enroll 25 adults with 1 to 3 metastases, each no larger than 5 cm.

This trial tests a highly targeted radiation technique called stereotactic body radiotherapy (SBRT) against standard radiotherapy for people whose cancer has spread to the spine but has not yet compressed the spinal cord. The goal is to see if SBRT can better prevent tumor growth…

This early study tests a new cell therapy called QH101 for people with solid tumors that have spread to the brain, spinal cord, or surrounding membranes. The therapy uses specially engineered immune cells designed to better recognize and attack cancer cells. The main goals are to…

This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants …

This study looks at whether giving focused radiation before surgery (neoadjuvant) or after surgery (adjuvant) works better to keep brain metastases from coming back. About 68 adults with 1 to 12 brain tumors will be randomly assigned to one of the two groups. Doctors will track t…

This study tests whether adding the targeted drug pirtobrutinib to standard chemotherapy (R-CHOP) works better than chemo alone for people with Richter transformation, a rare and aggressive lymphoma that develops from chronic lymphocytic leukemia. About 102 adults will be randoml…

This trial tests a drug called HRX215 in 80 adults with colorectal cancer that has spread to the liver. Before surgery to remove liver tumors, patients often get a procedure (PVE) that blocks blood flow to the tumor area to encourage the healthy part of the liver to grow. HRX215 …

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study tests whether giving a second, focused course of radiation to the breast is safe and effective for women whose breast cancer has returned more than a year after initial treatment. About 30 participants will receive accelerated partial breast irradiation. The goal is to…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This phase 2 trial compares a new type of radiation called LATTICE radiotherapy with standard palliative radiation for people who have large metastatic tumors (over 2.5 cm). The LATTICE method delivers a very high dose to the center of the tumor while keeping lower doses to the s…

This study tests a combination of three drugs—S-531011, fruquintinib, and pembrolizumab—in people with advanced colorectal cancer that has not responded to standard treatments. The cancer type is called MSS or pMMR, which typically does not respond well to immunotherapy alone. Th…

This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This study tests giving radiation therapy (SBRT) to the spine soon after surgery, while patients are still in the hospital, instead of waiting 2-4 weeks. The goal is to see if this faster approach is safe and helps control cancer growth in the spine. About 50 adults with cancer t…

This early-phase study tests a new mRNA-based treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment aims to control tumor growth by delivering a specific protein (IL-22BP) using a peptide carrier. The main goals are to check …

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This early-phase trial tests a new type of immunotherapy for adults with brain metastases from various cancers. The treatment uses the patient's own immune cells, modified to better target and attack tumor cells. The main goals are to see if the approach is safe and feasible in 1…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This phase 2 trial tests a new drug called zanzalintinib, taken as a pill, combined with a bone-strengthening agent for people with advanced kidney cancer that has spread to the bones. The study enrolls 20 participants whose cancer has worsened after 1–3 prior treatments, includi…

This Phase 2 trial tests whether combining two oral drugs, luvometinib and anlotinib, can shrink tumors in people with KRAS-mutated non-small cell lung cancer that has spread and stopped responding to prior treatment. About 48 adults will receive different dose combinations. The …

This study tests whether combining brain radiation with a targeted drug (dalpiciclib) and hormone therapy can help control breast cancer that has spread to the brain in people with HR-positive/HER2-negative disease. About 46 participants will receive the combination and be follow…

This phase 2 trial tests whether injecting an oncolytic virus (H101) directly into liver tumors, along with radiation, chemotherapy, targeted therapy, and immunotherapy, can shrink or control colorectal cancer that has spread to the liver and cannot be removed by surgery. The stu…

This phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and s…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. The goal is to see if the drug can shrink or control these brain tumors. Participants must have already had standard chemotherapy and be in…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This study tests whether giving radiation early to bone spots where cancer has spread can prevent complications like fractures or spinal cord pressure. About 90 adults with solid cancers that have spread to up to five bones will either get standard care or standard care plus radi…

This study looks at whether starting denosumab early, along with a standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults with liver cancer and bone metastases will be r…

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be r…

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and t…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …

This study will follow 130 people who had surgery for cancer that spread to the spine. Half will get radiation after surgery, half will not. Researchers want to see if radiation helps keep the cancer from coming back and improves how long patients live. The goal is to help doctor…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will…

This study tests whether drugs chosen to match specific DNA mutations in a patient's tumor can delay cancer worsening better than standard treatments. About 280 adults with metastatic or unresectable solid cancers will be randomly assigned to receive either DNA-matched therapy or…

This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Parti…

This study tests a precise, MRI-guided radiation treatment for people with cancer that has spread to the spine and is pressing on the spinal cord. The goal is to shrink the tumor enough to avoid surgery. About 24 adults with solid tumors like breast, prostate, or lung cancer will…

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is t…

This early-stage trial tests injecting the chemotherapy drug cisplatin directly into lung tumors using a thin tube with a camera. The goal is to see if this approach is safe and can kill more cancer cells while causing fewer side effects than standard IV chemo. The study will enr…

This early-stage trial tests a new oral drug called HLX97 in 138 people with advanced solid tumors (breast, prostate, or lung cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can slow tumor g…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along…

This early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…

This early-stage trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced or metastatic solid tumors who have no standard treatment options left. The main goal is to find a safe dose and check for side effects. Resear…

This study tests a new way to treat people with many metastatic tumors, including at least one large one. It combines two local treatments—freezing (cryoablation) and placing tiny radioactive seeds—to better control the cancer. The goal is to see if this personalized approach wor…

This study tests a new drug called EMB-07, which is a bispecific antibody that helps the immune system attack cancer cells. It is for people with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or whose cancer has come back. The trial will check safety, side effect…

This early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…

This phase II trial tests a combination of two drugs—Utidelone and Toripalimab—in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkage …

This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…

This phase 2 trial tests whether adding image-guided radioactive seed implants to standard cancer therapy can improve disease control in patients with 6 to 10 metastatic tumors. About 120 adults with solid tumors that have spread will be randomly assigned to receive either standa…

This Phase 3 trial will compare two radiation approaches for people with large brain metastases (tumors that spread from other cancers). One group gets a single high-dose radiation before surgery; the other gets five smaller doses of radiation alone. The goal is to see which meth…

This study tests whether a new drug called IP-001, injected into the liver after standard heat-based tumor destruction, can help prevent colorectal cancer from coming back. About 717 adults with colorectal cancer that has spread only to the liver will be randomly assigned to rece…

This study tests whether giving a combination of intravenous iron, erythropoietin (EPO), and tranexamic acid before bone tumor surgery can improve hemoglobin levels and reduce the need for blood transfusions compared to usual care. The trial enrolls 160 adults with anemia or iron…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This study tests two experimental drugs, ANS014004 and PLB1004, given together to people with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially…

This study tests a highly precise type of radiation called SBRT for people with kidney cancer who cannot undergo surgery. The treatment uses a robotic system (CyberKnife) to deliver high-dose radiation directly to the tumor while sparing healthy tissue. Researchers will track 60 …

This study tests a custom 3D-printed implant designed to rebuild the spine after removing a tumor. The implant is less rigid than traditional ones, which may help bone grow better and reduce sinking. Researchers will follow 18 adults for safety and how well the implant fuses with…

This phase 3 trial tests a new method called PIPAC that delivers chemotherapy as a pressurized mist directly into the abdomen during a minimally invasive procedure. It compares this approach plus standard intravenous chemo (FOLFIRI) to standard chemo alone for people with appendi…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This study tests a new drug combination (QLC5513 plus QL1706, with or without platinum chemo) in people with advanced solid tumors that have spread. The goal is to see if the treatment can shrink tumors and to check its safety. About 290 participants will take part, and the study…

This clinical trial tests a new drug called BPR-6023021, which is a radioactive compound designed to target bone. It is for people with advanced solid tumors that have spread to the bone and who have no other standard treatment options. The study will enroll 195 participants to e…

This trial tests a program called ONLOOP that reminds adult survivors of childhood cancer to get important screening tests. These tests can find late effects like heart disease or second cancers early. About 900 survivors in Ontario will be randomly assigned to get the reminders …

This early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals …

This study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrin…

This phase 3 trial compares two radiation schedules for people with 1 to 5 brain metastases from cancers like melanoma, kidney, or sarcoma. One group gets radiation on days 1, 3, and 5; the other on days 1, 2, and 3. The goal is to see if the shorter schedule controls tumor growt…

This study tests a device that uses both freezing and heating to destroy liver tumors in people with liver cancer or colorectal cancer that has spread to the liver. The goal is to see if this approach improves how long patients live without their cancer growing, and whether it ac…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This study tests whether a type of PET scan that tracks amino acids can accurately tell apart radiation necrosis (dead tissue from treatment) from tumor regrowth in people who have had radiation for brain metastases. About 80 patients who already received this PET scan will have …

This study will test whether combining PET scans with amino acid tracers and MRI can more accurately diagnose brain tumors and tell if they are growing or just reacting to treatment. Researchers will follow 270 adults with primary or secondary brain tumors, comparing the new imag…

This study tests an artificial intelligence (AI) model designed to detect bone lesions on whole-body PET/CT scans. Researchers will enroll 180 adults with suspicious bone findings to see how well the AI can tell benign from malignant lesions, and predict tumor type, genetics, and…

This study will test whether a special CT scan (dual-energy CT) can be as good as MRI for mapping tumors and healthy organs before radiation therapy. Researchers will enroll 80 people with brain, bone, head/neck, or lung cancer. If DECT works well, it could save time and money co…

This study tests whether taking S-adenosylmethionine (SAMe), a natural supplement, can prevent liver injury caused by the chemotherapy drug oxaliplatin. About 30 adults with colorectal cancer that has spread to the liver will take SAMe pills daily for 3-6 months alongside their c…

This trial tests a program that combines palliative care with remote monitoring and telehealth to better support people with advanced cancer. Participants complete questionnaires and physical exams, and their care is tailored to their needs. The study includes 300 adults with met…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study tests a device called Scrambler Therapy to relieve nerve pain in children with cancer that has spread to the bone. The treatment is non-invasive and aims to lower pain levels and reduce the need for pain medications. About 70 children who can describe their pain will t…

This study tests whether a special glass-based bone cement, used with ultrasound during surgery, can safely stabilize bones and reduce pain in people with advanced cancer that has spread to the pelvis. Eight adults aged 18 to 80 with painful pelvic bone tumors will receive the tr…

This study looks at whether interventional radiology—a minimally invasive technique using needles or probes—can reduce pain and improve daily life for people with advanced or metastatic cancer. About 125 adults whose cancer has spread and who are expected to live at least 3 month…

This study tests whether a small, non-invasive device that stimulates a nerve in the ear can help reduce fatigue in cancer patients receiving immunotherapy. Thirteen adults with advanced cancer and significant fatigue will use the device at home for 60 minutes daily over six week…

This study tests whether a supervised exercise program combining resistance training and walking can improve physical function, fitness, and quality of life in women with stage IV breast cancer. 78 women currently on medical treatment will be randomly assigned to either the exerc…

This study tests whether personalized cooking and food guidance can help slow muscle loss in people with advanced cancer who are on chemotherapy. About 200 adults will be split into two groups: one gets standard nutrition care plus exercise advice, and the other gets the same plu…

This study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly…

This study tests if a special cooling cap can reduce hair loss in people with advanced solid tumors who are receiving a type of chemotherapy called antibody-drug conjugates (ADCs). About 102 women will be split into two groups: one gets the cooling cap during treatment, the other…

This study tests whether adding telephone health coaching to a symptom management handbook helps reduce symptom burden and improve quality of life for people with metastatic breast, GI, or melanoma cancer and their caregivers. About 200 participants will be split into two groups:…

This study tests whether using a lung perfusion PET/CT scan to guide radiation planning can reduce lung injury compared to standard anatomical planning. About 418 adults with lung tumors receiving stereotactic body radiotherapy (SBRT) will be randomly assigned to one of the two p…

This study compares standard palliative radiotherapy (24 Gray in 3 sessions) with a higher dose (27 Gray in 3 sessions) for people with large metastatic tumors. The goal is to see if the higher dose improves tumor control without more side effects. About 20 adults with solid tumo…

This study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…

This trial tests an AI tool called MIDI that quickly spots problems in brain MRI scans. The goal is to see if it helps doctors report urgent scans faster, so patients get treatment sooner. Over 100,000 adults will take part across multiple NHS sites in the UK.

This study follows 200 adults with stage 4 breast cancer that has spread to the brain or spinal lining. Participants fill out questionnaires about their symptoms, thinking abilities, and physical function over time. The goal is to track how symptoms change and how treatments affe…

This observational study looks at adults with non-small cell lung cancer that has spread to the brain. Researchers want to see if getting radiation and immunotherapy 30 days apart or closer together changes how long the brain tumors stay stable and how long patients live. Partici…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This early-phase trial will test a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. The goal is to see if the imaging agent can safely tell the difference between tum…

This study will test an artificial intelligence system designed to give early warning of cancer spreading to other parts of the body. Current imaging can only see larger tumors, but this AI analyzes routine scans and patient data to detect signs of microscopic spread. Researchers…

This study looks at how well immunotherapy shrinks tumors and lymph node metastases in 5,000 people with various cancers. Researchers will track changes in tumor and lymph node size after treatment and explore factors like beta-blocker use that might affect results. The goal is t…

This study follows 150 adults with paralysis from spinal tumors who undergo surgery to relieve pressure on the spinal cord. Researchers track how well patients recover movement, bladder and bowel function, and quality of life over one year. The goal is to identify factors that he…

This study will test a new single-port surgical robot, called SHURUI, for chest surgeries like removing lung tumors or mediastinal masses. About 40 adults aged 18-75 who need these surgeries will take part. The goal is to see if the robot is safe and works well, with hopes of les…

This study looks at how cancer care is provided in oncology and supportive care clinics. Researchers will collect feedback from 200 adults with advanced solid tumors to better understand and improve care delivery. The goal is to help doctors learn from patient experiences, not to…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study looks at whether audio recording a clinic visit helps advanced cancer patients remember what their doctor said and share it with family. About 200 patients at MD Anderson Cancer Center will be asked to record part of their visit and later report if it was useful. The g…

This study enrolls 30 people with cancer that has spread (metastasized). Researchers take a sample of the tumor and analyze its RNA to see if they can predict where the cancer originally started. No treatment is given; the goal is to see how accurate the RNA test is at identifyin…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study looks at two different lengths of time for stopping blood flow to the liver during surgery for liver cancer. 600 adults will be randomly assigned to either a 15-minute or 45-minute pause in blood flow. The goal is to see if the longer pause is just as safe and does not…